Pomegra
Ours Privacy raised a multiple-times-oversubscribed $15M Series A co-led by Lightbank and Health Velocity Capital, giving its HIPAA-safe customer data platform fresh capital as healthcare marketers scramble for compliant alternatives to standard tracking pixels.
Key Takeaways
- Ours Privacy closed a $15M Series A on August 19, 2026, co-led by Lightbank and Health Velocity Capital.
- The round was multiple-times-oversubscribed; valuation was not disclosed.
- The platform now serves 200+ healthcare organizations, from digital health startups to multibillion-dollar health systems.
Lead
Ours Privacy, the Houston-based healthcare customer data platform, announced its $15M Series A on August 19, 2026. The round was co-led by Lightbank and Health Velocity Capital, with participation from Rock Health, Lakehouse, TMV, Switch Ventures, Starfire Ventures, and GreyMatter. The deal was multiple-times-oversubscribed. Post-money valuation was not disclosed.
What Does Ours Privacy Actually Do?
The company intercepts data before it reaches ad platforms, not after. Its server-side tracking layer sits between a healthcare organization's website or app and destinations like Google Ads or Meta, stripping protected health information before any packet leaves the premises. The result is a signed business associate agreement with each client, giving that client a defensible HIPAA compliance posture for its digital marketing stack.
That is a narrower pitch than a general-purpose CDP. Ours Privacy is not competing with Salesforce Data Cloud or Segment for enterprise data architecture. It is displacing the chaos of browser pixels at health systems and telehealth brands that ran into legal exposure after the Office for Civil Rights clarified, in 2022, that routing PHI to tracking vendors without a BAA can constitute a HIPAA violation. Many organizations responded by turning off tracking entirely, losing visibility into which ad campaigns were actually driving patient acquisition.
Ours Privacy sells the restore: compliant tracking, campaign attribution, and a consent management layer, bundled in a platform that also now includes A/B testing and advanced analytics. The company calls itself the first healthcare CDP to bundle integrated A/B testing and personalization in a single compliant environment.
Why Is This Round Oversubscribed?
Regulatory pressure on health data has not let up. State-level privacy laws added after the 2022 OCR guidance extended exposure beyond traditional covered entities to a wider population of digital health companies. Each new enforcement action, settlement, or class-action filing tied to tracking pixels generates a fresh wave of inbound inquiries for vendors offering defensible alternatives. That pipeline dynamic, combined with early customer traction across 200-plus organizations spanning digital health startups and multibillion-dollar health systems, made the story easy to underwrite.
Lightbank has a history of backing infrastructure-oriented B2B software companies from Chicago. Health Velocity Capital focuses specifically on healthcare IT, giving the syndicate credibility with enterprise buyers who need investor names their compliance and procurement teams recognize. Rock Health, which participated in an earlier round, doubled down - a signal of continued conviction in the category.
The founders - Jessica Holton, Adam Putterman, and Tyler Zey - built the initial version of the platform while running Ours Wellness, a telehealth company. They could not find compliant marketing infrastructure off the shelf, so they built it. That origin story matters for sales: the team speaks practitioner fluency to healthcare marketers, not just to compliance officers.
How Does This Change the Competitive Picture?
Before this round, the HIPAA-compliant analytics and CDP space was fragmented among smaller, point-solution vendors and a few compliance-focused analytics tools with limited ad-platform integrations. The $15M infusion positions Ours Privacy to hire sales and engineering aggressively and potentially set the pace for what full-stack compliance infrastructure looks like in healthcare marketing.
The risk is that large incumbent CDPs and analytics platforms accelerate their own BAA offerings. Salesforce, Adobe, and several analytics vendors already offer BAA coverage for some products, though coverage is often partial and ad-platform integrations remain complicated. A well-funded Ours Privacy needs its product breadth advantage to outrun the incumbents' compliance coverage expansion.
Strategic Context
The timing reflects a maturation in how healthcare organizations think about patient data. A year or two ago, compliance teams were primarily focused on stopping the bleeding from existing pixel exposure. The conversation has shifted toward building a durable, performant marketing infrastructure that does not require choosing between analytics visibility and regulatory safety. That shift is Ours Privacy's opportunity - and also an argument for why the platform's A/B testing and advanced analytics additions are strategically sound rather than feature sprawl.
New capital will go toward scaling operations and accelerating enterprise adoption.
Outlook
The $15M will test whether Ours Privacy can move from 200 clients to 2,000 without the product fracturing under enterprise complexity. The oversubscription signals genuine investor conviction, but the category itself remains young and the enforcement calendar is unpredictable. If OCR enforcement slows, so does urgency among prospective buyers. If it accelerates, so does competition for the same clients. Either way, the company enters the next stage with strong syndicate backing, a founding team that has operated in the space it is selling into, and enough runway to find out whether HIPAA-compliant marketing infrastructure is a standalone category or a feature that the platforms eventually absorb.
